Early stage financing for MyeloPro


Friday, October 6, 2017


MyeloPro Diagnostics and Research GmbH (MyeloPro) obtains funding from the Austrian Research Promotion Agency (FFG) and the Austria Wirtschaftsservice Gesellschaft (AWS SEED program) to complete discovery program of CALR targeting therapeutics and establish its infrastructure to face the start of preclinical development. Non-dilutive federal funding allows  to maintain independence and provides resources in addressing the high medical need of rare, orphan blood malignancies called myelopoliferative neoplasms (MPNs).



About MyeloPro

MyeloPro is a discovery stage, Vienna (Austria) based biopharmaceutical company, developing therapeutics to treat myeloproliferative neoplasms. MyeloPro obtained a worldwide, exclusive therapeutic license from CeMM of the Austrian Academy of Science to target the mutant form of calreticulin (CALR). MyeloPro is actively seeking private investor partners for preclinical development of its most promising development candidates.


Contact information

Oleh Zagrijtschuk, MD

General Manager

MyeloPro Diagnostics and Research GmbH

Lazarettgasse 14, BT25.3, CeMM building, level 3, 1090 Vienna

Phone: +43 664 882 62 093


BIO-Europe Spring 2017

Meet MyeloPro at BIO-Europe Spring in Barcelona, March 20-22, 2017


Thursday, February 16, 2017


The founders of MyeloPro will attend the BIO-Europe partnering conference in Barcelona to present the company, find partners, service providers and secure future financing.

MyeloPro’s presentation: Tuesday 21st of March, 10:50am, Room 120, Level 1

MyeloPro acquires an exclusive worldwide license from CeMM to develop therapeutics targeting mutated calreticulin protein in malignant diseases


Wednesday, October 12, 2016

CALR mutations have been discovered by the research team of Robert Kralovics at CeMM as highly disease-specific markers to a blood cancer called myeloproliferative neoplasms (MPN). Recently, the relevance of CALR mutations have been recognized by the WHO, including them as one of the major diagnostic criteria.


As a unique, disease-specific peptide, mutated CALR is also an attractive target to develop therapies.  “This licensing agreement enables MyeloPro to continue research on the therapeutic exploitation of mutated CALR in a disease area with an unmet medical need. We are making progress and are very excited to partner with CeMM, a world-class research institution“, states Oleh Zagrijtschuk, CEO of MyeloPro. The above mentioned license agreement excludes diagnostic use of the CALR mutation.

The mission of CeMM is to achieve maximum innovation in precise and personalized molecular medicine to improve healthcare. A committed team of scientists and medical doctors pursue free basic research in the life sciences fully engrafted in a large and vibrant hospital environment of great medical tradition and practice. Partnerships with biotech or pharma companies facilitates following upon research results by providing solutions to medical doctors and patients.



1. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E,Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013 Dec 19;369(25):2379-90.


2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloidneoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405